The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Acrux (ACR) receives approval from the US FDA to review a generic version of its nitroglycerin ointment at 0.4 per cent concentration
  • The company applied for an abbreviated new drug application for the generic version, if approved by the FDA will allow ACR to market the generic ointment to patients
  • Nitroglycerin ointment is used to treat moderate to severe pain associated with chronic anal fissures
  • The total addressable market for the current product is almost US$19.9 million
  • Shares rose 9.52 per cent to 4.6 cents at 12:59 pm AEST

Acrux (ACR) has received approval from the United States Food and Drug Administration (FDA) to review a generic version of its nitroglycerin ointment at 0.4 per cent concentration.

The company applied for an abbreviated new drug application for the generic version which, if approved by the FDA will allow ACR to market the generic ointment to patients.

Nitroglycerin ointment is used to treat moderate to severe pain associated with chronic anal fissures.

The original drug is currently listed as Rectiv Ointment, 0.4 per cent, and marketed by AbbVie in the US.

The total addressable market for the current product is almost US$19.9 million (A$29.7 million) with no FDA-approved generic version of the ointment available on the US market.

Acrux is currently advancing a variety of other topical products which are in varying stages of development, totalling 16 products.

Acrux shares rose 9.52 per cent to 4.6 cents at 12:59 pm AEST.

ACR by the numbers
More From The Market Online
The Market Online Video

ASX Daily Close: ASX matches futures prediction on a green Friday | 21 June 2024

The ASX200 reversed its trend to end the week in the green, up 0.35%. Nearly all…
The Market Online Video

ASX Market Update: Stocks swing from green with energy to remorseful red | 21 June, 2024

The ASX200 came out the gate in the green on Friday, but slipped well below the red line within the first hour of

Week 25 Wrap: No RBA cut yet; India stocks shake off Modi jitters; China concerns remain

The RBA keeps rates on pause; Guzman Gomez falls nearly -5% on Friday; Droneshield's new ATH;…

Plagues precede widespread power shifts. We’re living in one – and minerals are at the fore

The one defining feature of our post-COVID 'new normal' is a USA swing towards domestic supply…